Ulcerative colitis (UC) is a chronic inflammatory bowel disease, traditionally regarded as being limited to the colorectum. Although several gastroduodenal lesions have been reported in cases of UC, in general, duodenal lesions in UC are believed to be uncommon and gastric lesions in UC are a rare presentation. In this report, we presented a 66-year-old lady with upper GI presentation with gastroduodenal ulcerative colitis accompanying pancolonic UC.
Most of the colonic submucosal mesenchymal polyps are benign tumors. They are formed by more than one type of mesenchymal tissue. The diagnosis of angiolipofibroma depends on the histological findings with the proliferation of vascular, fatty, and fibrous connective tissues. Majority of angiolipofibromas are arising in the kidney and have rare presentation as extra renal region. Here we report a case of 58-year-old female patient with angiolipofibroma of sigmoid colon (8.5 cm x 4 cm size) which was treated successfully with surgical resection. The clinical presentation, operative procedure, pathological features, and medical literature review are presented.
Introduction
Helicobacter pylori infection in dyspepsia is an important clinical problem with increasing antibiotic resistance.
Aim
To evaluate the efficacy of levofloxacin‐based triple therapy compared with clarithromycin‐based triple therapy for Helicobacter pylori eradication in chronic dyspepsia.
Methods
This was a prospective, single‐blinded randomized trial. Rapid urease test and histology were performed in patients with chronic dyspepsia who underwent gastroscopy. H pylori‐infected patients were randomly allocated into two equal groups prescribing 10‐day course of levofloxacin‐based or clarithromycin‐based regime. Endoscopic responses and eradication status of both regimes were rechecked with gastroscopy 4 weeks after therapies.
Result
Two hundred and ninety‐one treatment‐naïve patients were enrolled. Eradication rates were 40% vs 47.5% on intention to treat (ITT) analysis and 43.7% vs 50.8% on per‐protocol (PP) for clarithromycin group vs levofloxacin group, respectively. In levofloxacin arm, eradication occurred in 62.5% (ITT) & 71.4% (PP) of ulcer dyspepsia and 43.2% (ITT) and 46.6% (PP) of nonulcer dyspepsia.
Among ulcer dyspepsia, 58.3% healed in clarithromycin group and 64.3% in levofloxacin group. In nonulcer dyspepsia, gastritis was resolved in 21% of clarithromycin group and 10% of levofloxacin group. Adverse effects occurred in 30% of clarithromycin group and 27.6% of levofloxacin group.
Conclusion
In the study, eradication rates of both therapies were very low to unacceptable level. Levofloxacin was not effective in both ulcer and nonulcer dyspepsia. The emergence of primary levofloxacin resistant strains due to widespread usages in various infections might be the reason.
Digital signage is ultimately less costly and more efficient than print, while delivering greater message control and a more engaged audience. LED display, as the board size is getting larger, the time needed for data transfer between LED dot matrix arrays is also very important using display technology, video technology, multimedia technology, network technology, computer technique and automatic control technology to display various information factors. In this paper, first using of Altium Designer, is a PCB design software. Designers provide consistent and standardized project file, create the right parts for design and then made of PCB board is proposed. As the main functional unit, the proposed method uses the PSoC analog coprocessor, octal transparent D-type latches and high speed CMOS Decoder/De-multiplexer are deployed. In addition, DC to Dc power converter and a power MOSFET transistor are used.
I.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.